MCID: DBT002
MIFTS: 41

Diabetic Autonomic Neuropathy

Categories: Neuronal diseases

Aliases & Classifications for Diabetic Autonomic Neuropathy

MalaCards integrated aliases for Diabetic Autonomic Neuropathy:

Name: Diabetic Autonomic Neuropathy 12 54 15 71
Diabetic Neuropathies 43 71

Classifications:



External Ids:

Disease Ontology 12 DOID:11503
MeSH 43 D003929
NCIt 49 C27068
SNOMED-CT 67 50620007
UMLS 71 C0011882 C0271686

Summaries for Diabetic Autonomic Neuropathy

MalaCards based summary : Diabetic Autonomic Neuropathy, also known as diabetic neuropathies, is related to microvascular complications of diabetes 1 and microvascular complications of diabetes 5, and has symptoms including sciatica and neuralgia. An important gene associated with Diabetic Autonomic Neuropathy is AKR1B1 (Aldo-Keto Reductase Family 1 Member B), and among its related pathways/superpathways are p70S6K Signaling and Peptide hormone metabolism. The drugs Quinapril and Bromocriptine have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and skin, and related phenotype is cardiovascular system.

Related Diseases for Diabetic Autonomic Neuropathy

Diseases related to Diabetic Autonomic Neuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(showing 373, show less)
# Related Disease Score Top Affiliating Genes
1 microvascular complications of diabetes 1 33.1 NTF3 NGF INS AKR1B1
2 microvascular complications of diabetes 5 32.3 INS AKR1B1 ACE
3 gastroparesis 30.6 MLNR MLN GAST
4 iritis 30.5 EPO ACE
5 silent myocardial infarction 30.4 INS ACE
6 neurogenic arthropathy 30.4 NGF INS
7 algoneurodystrophy 30.3 NGF INS
8 pure autonomic failure 30.3 REN EPO ACE
9 diabetic encephalopathy 30.1 NGF INS
10 pylorospasm 30.1 MLNR MLN
11 duodenal ulcer 30.0 MLN INS GAST
12 sensory peripheral neuropathy 30.0 NTF3 NGF AKR1B1
13 polyneuropathy 29.9 NGF INS EPO AKR1B1 ACE
14 prediabetes syndrome 29.9 INS GCG ACE
15 diabetic polyneuropathy 29.8 NTF3 NGF INS AKR1B1
16 peripheral nervous system disease 29.8 NTF3 NGF INS GCG AKR1B1 ACE
17 peripheral vascular disease 29.5 INS GAST EPO ACE
18 hypertension, diastolic 29.5 REN ACE
19 vascular disease 29.4 REN INS EPO ACE
20 sleep apnea 29.4 REN INS EPO ACE
21 constipation 29.4 NTF3 MLNR MLN GCG GAST AKR1B1
22 microvascular complications of diabetes 3 29.3 REN INS AKR1B1 ACE
23 nasopharyngitis 29.3 INS GCG
24 sleep disorder 29.2 REN INS ACE
25 uremia 29.1 REN INS EPO ACE
26 diabetic neuropathy 28.9 REN NTF3 NGF INS EPO AKR1B1
27 diabetes mellitus, insulin-dependent 28.8 REN PPY INS GCG AKR1B1 ACE
28 apnea, obstructive sleep 28.7 REN INS GCG ACE
29 congestive heart failure 28.7 REN INS EPO ACE
30 diabetes mellitus 28.6 REN MLN INS GCG EPO AKR1B1
31 chronic kidney disease 28.6 REN INS EPO ACE
32 autonomic neuropathy 28.6 REN PPY NTF3 NGF MLNR MLN
33 pheochromocytoma 28.4 REN NGF MLN EPO ACE
34 kidney disease 28.4 REN INS GCG EPO AKR1B1 ACE
35 diabetes mellitus, noninsulin-dependent 28.2 REN PPY NGF INS GCG AKR1B1
36 body mass index quantitative trait locus 11 28.0 REN MLN INS GCG AKR1B1 ACE
37 microvascular complications of diabetes 2 11.4
38 neuropathy 11.1
39 abducens nerve disease 11.1
40 argyll robertson pupil 11.1
41 fainting 11.1
42 syncope 11.1
43 autonomic dysfunction 10.6
44 hypoglycemia 10.5
45 erythematosquamous dermatosis 10.5 INS GCG
46 hirata disease 10.4 INS GCG
47 hypoglycemic coma 10.4 INS GCG
48 acute insulin response 10.4 INS GCG
49 sheehan syndrome 10.4 INS EPO
50 functional colonic disease 10.4 MLNR MLN
51 mononeuropathy 10.4
52 colonic pseudo-obstruction 10.4 MLNR MLN
53 alzheimer disease 6 10.4 INS GCG
54 lipid metabolism disorder 10.3
55 chronic pain 10.3
56 paresthesia 10.3
57 asphyxia neonatorum 10.3 INS EPO
58 postcholecystectomy syndrome 10.3 MLN GAST
59 impotence 10.3
60 mononeuritis of lower limb 10.3 NTF3 NGF
61 duodenal somatostatinoma 10.3 PPY INS
62 auditory system cancer 10.3 PPY GCG
63 lumbosacral plexus lesion 10.3 NTF3 NGF
64 lesion of sciatic nerve 10.3 NTF3 NGF
65 erythermalgia, primary 10.3
66 duodenitis 10.3 INS GAST
67 slowed nerve conduction velocity, autosomal dominant 10.3
68 cardiac conduction defect 10.3
69 resting heart rate, variation in 10.3
70 diarrhea 10.2
71 neuroaxonal dystrophy 10.2
72 non-functioning pancreatic endocrine tumor 10.2 PPY GAST
73 idiopathic edema 10.2 INS ACE
74 ocular dominance 10.2 NTF3 NGF
75 arthropathy 10.2
76 duodenogastric reflux 10.2 MLN GAST
77 endometrial small cell carcinoma 10.2 PPY GAST
78 carpal tunnel syndrome 10.2
79 esophageal neuroendocrine tumor 10.2 PPY GAST
80 hyperglycemia 10.2
81 postherpetic neuralgia 10.2
82 cataract 38 10.2 NTF3 NGF
83 vitamin metabolic disorder 10.1 GAST EPO
84 pain agnosia 10.1
85 background diabetic retinopathy 10.1 INS AKR1B1 ACE
86 macular retinal edema 10.1 INS AKR1B1 ACE
87 amyotrophic lateral sclerosis 1 10.1
88 lateral sclerosis 10.1
89 dysautonomia 10.1
90 short bowel syndrome 10.1 GCG GAST AOC1
91 axonal neuropathy 10.1
92 wallerian degeneration 10.1
93 insulinoma 10.1 INS GCG GAST
94 maturity-onset diabetes of the young, type 1 10.1 INS GCG ACE
95 teratoma 10.1 NGF INS GCG
96 cough variant asthma 10.1 NGF ACE
97 polyradiculopathy 10.1 NGF AKR1B1
98 neuropathy, painful 10.1
99 rickets 10.1
100 radiculopathy 10.1
101 demyelinating polyneuropathy 10.1
102 fibromyalgia 10.1
103 muscular atrophy 10.1
104 vasculitis 10.1
105 duodenal gastrinoma 10.0 PPY GCG GAST
106 pancreatic cholera 10.0 PPY GCG GAST
107 pancreatic gastrinoma 10.0 PPY GCG GAST
108 gastroesophageal reflux 10.0 MLN GCG GAST
109 atrial standstill 1 10.0
110 cardiac arrhythmia 10.0
111 myocardial infarction 10.0
112 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 10.0
113 microvascular complications of diabetes 4 10.0
114 microvascular complications of diabetes 6 10.0
115 microvascular complications of diabetes 7 10.0
116 sexual disorder 10.0
117 severe combined immunodeficiency 10.0
118 dysphagia 10.0
119 exanthem 10.0
120 chronic inflammatory demyelinating polyradiculoneuropathy 10.0
121 herpes simplex 10.0
122 zollinger-ellison syndrome 10.0 PPY MLN GAST
123 postgastrectomy syndrome 10.0 MLN INS GCG GAST
124 dumping syndrome 10.0 MLN INS GCG GAST
125 hypertriglyceridemia, familial 10.0
126 polykaryocytosis inducer 10.0
127 mammary-digital-nail syndrome 10.0
128 restless legs syndrome 10.0
129 charcot-marie-tooth disease 10.0
130 glucose intolerance 10.0
131 benign essential hypertension 9.9 REN INS
132 retinal microaneurysm 9.9 REN INS AKR1B1
133 ataxia and polyneuropathy, adult-onset 9.9
134 anxiety 9.9
135 vitamin b12 deficiency 9.9
136 neurogenic bladder 9.9
137 arteriosclerosis 9.9
138 cerebrovascular disease 9.9
139 cataract 9.9
140 cytokine deficiency 9.9
141 depression 9.9
142 neurodegeneration with brain iron accumulation 2a 9.9
143 ocular motor apraxia 9.9
144 insulin-like growth factor i 9.9
145 homocysteinemia 9.9
146 ventricular fibrillation, paroxysmal familial, 1 9.9
147 reflex sympathetic dystrophy 9.9
148 body mass index quantitative trait locus 1 9.9
149 anorexia nervosa 9.9
150 coronary heart disease 1 9.9
151 syndactyly, mesoaxial synostotic, with phalangeal reduction 9.9
152 adrenal gland pheochromocytoma 9.9
153 atrial fibrillation 9.9
154 gallbladder disease 9.9
155 anhidrosis 9.9
156 heart disease 9.9
157 pyelonephritis 9.9
158 esophagitis 9.9
159 allergic hypersensitivity disease 9.9
160 bronchopneumonia 9.9
161 peptic esophagitis 9.9
162 neuritis 9.9
163 hyperinsulinism 9.9
164 gastric dilatation 9.9
165 aspiration pneumonitis 9.9
166 neuroblastoma 9.9
167 acute myocardial infarction 9.9
168 47,xyy 9.9
169 48,xyyy 9.9
170 brittle diabetes 9.9
171 broken heart syndrome 9.9
172 primary orthostatic hypotension 9.9
173 hypoxia 9.9
174 rapidly involuting congenital hemangioma 9.9
175 pancreatic endocrine carcinoma 9.9 PPY INS GCG GAST
176 diabetic macular edema 9.9 REN EPO AKR1B1
177 somatostatinoma 9.9 PPY INS GCG GAST
178 pancreatic cystadenoma 9.9 PPY INS GCG GAST
179 islet cell tumor 9.9 PPY INS GCG GAST
180 gastrointestinal system benign neoplasm 9.9 PPY INS GCG GAST
181 multiple endocrine neoplasia, type i 9.9 PPY INS GCG GAST
182 endocrine pancreas disease 9.8 REN INS GCG
183 hypoaldosteronism 9.8 REN ACE
184 renal artery obstruction 9.8 REN ACE
185 orthostatic proteinuria 9.8 REN ACE
186 galactosemia 9.8
187 leprosy 3 9.8
188 yemenite deaf-blind hypopigmentation syndrome 9.8
189 orthostatic intolerance 9.8
190 ataxia, combined cerebellar and peripheral, with hearing loss and diabetes mellitus 9.8
191 angina pectoris 9.8
192 peripheral artery disease 9.8
193 bone resorption disease 9.8
194 osteomyelitis 9.8
195 tooth disease 9.8
196 diabetic angiopathy 9.8
197 hemosiderosis 9.8
198 guillain-barre syndrome 9.8
199 alcoholic neuropathy 9.8
200 alcohol use disorder 9.8
201 mononeuritis multiplex 9.8
202 motor neuron disease 9.8
203 complex regional pain syndrome 9.8
204 ischemia 9.8
205 intermittent claudication 9.8
206 plexopathy 9.8
207 myopathy 9.8
208 burning mouth syndrome 9.8
209 ulnar neuropathy 9.8
210 elephantiasis 9.8
211 erythromelalgia 9.8
212 glossodynia 9.8
213 hansen's disease 9.8
214 back pain 9.8
215 encephalopathy 9.8
216 temporomandibular joint anomaly 9.8
217 lymphedema 9.8
218 cholesterol embolism 9.8 REN ACE
219 retinal degeneration 9.8 NTF3 NGF EPO AKR1B1
220 kidney papillary necrosis 9.8 REN ACE
221 disease of mental health 9.8 NGF INS ACE
222 systemic scleroderma 9.8 MLN INS GAST ACE
223 malignant essential hypertension 9.8 REN ACE
224 fibromuscular dysplasia 9.8 REN ACE
225 hypertensive retinopathy 9.7 REN ACE
226 hydrocephalus 9.7 NTF3 NGF EPO ACE
227 generalized atherosclerosis 9.7 REN INS ACE
228 potter's syndrome 9.7 REN INS ACE
229 kidney hypertrophy 9.7 REN INS ACE
230 hypertensive encephalopathy 9.7 REN EPO ACE
231 intermediate coronary syndrome 9.7 REN INS ACE
232 renal artery disease 9.7 REN EPO ACE
233 alcohol dependence 9.7
234 arteries, anomalies of 9.7
235 atherosclerosis susceptibility 9.7
236 progressive familial heart block, type ia 9.7
237 multiple sclerosis 9.7
238 hypercholesterolemia, familial, 1 9.7
239 lipomatosis, multiple 9.7
240 multicentric carpotarsal osteolysis syndrome 9.7
241 platelet aggregation, spontaneous 9.7
242 trigeminal neuralgia 9.7
243 arterial calcification, generalized, of infancy, 1 9.7
244 friedreich ataxia 9.7
245 hemochromatosis, type 1 9.7
246 acetylation, slow 9.7
247 myasthenia gravis 9.7
248 pancreatic agenesis 1 9.7
249 paine syndrome 9.7
250 stroke, ischemic 9.7
251 body mass index quantitative trait locus 9 9.7
252 body mass index quantitative trait locus 8 9.7
253 abdominal obesity-metabolic syndrome 1 9.7
254 maturity-onset diabetes of the young 9.7
255 body mass index quantitative trait locus 4 9.7
256 body mass index quantitative trait locus 10 9.7
257 diabetes mellitus, noninsulin-dependent, 4 9.7
258 body mass index quantitative trait locus 7 9.7
259 congenital disorder of glycosylation, type in 9.7
260 diabetes mellitus, ketosis-prone 9.7
261 body mass index quantitative trait locus 12 9.7
262 body mass index quantitative trait locus 14 9.7
263 muscle hypertrophy 9.7
264 body mass index quantitative trait locus 18 9.7
265 hydrops, lactic acidosis, and sideroblastic anemia 9.7
266 spastic paraplegia, intellectual disability, nystagmus, and obesity 9.7
267 body mass index quantitative trait locus 19 9.7
268 encephalopathy, progressive, early-onset, with episodic rhabdomyolysis 9.7
269 gastrointestinal ulceration, recurrent, with dysfunctional platelets 9.7
270 body mass index quantitative trait locus 20 9.7
271 lennox-gastaut syndrome 9.7
272 limb ischemia 9.7
273 oligoasthenoteratozoospermia 9.7
274 postural orthostatic tachycardia syndrome 9.7
275 sensorineural hearing loss 9.7
276 neuroretinitis 9.7
277 pleomorphic lipoma 9.7
278 prostatic hypertrophy 9.7
279 pertussis 9.7
280 respiratory failure 9.7
281 gestational diabetes 9.7
282 choledocholithiasis 9.7
283 ischemic neuropathy 9.7
284 spinal muscular atrophy 9.7
285 tarsal tunnel syndrome 9.7
286 capillary disease 9.7
287 gout 9.7
288 porphyria 9.7
289 exocrine pancreatic insufficiency 9.7
290 color blindness 9.7
291 cholestasis 9.7
292 beriberi 9.7
293 generalized anxiety disorder 9.7
294 mental depression 9.7
295 cholecystitis 9.7
296 keratopathy 9.7
297 iron metabolism disease 9.7
298 pancreas disease 9.7
299 glycogen storage disease 9.7
300 carbohydrate metabolic disorder 9.7
301 anuria 9.7
302 neurilemmoma 9.7
303 demyelinating disease 9.7
304 embryonal carcinoma 9.7
305 mood disorder 9.7
306 purpura 9.7
307 retinitis 9.7
308 skin disease 9.7
309 verrucous carcinoma 9.7
310 cranial nerve palsy 9.7
311 gastritis 9.7
312 liver disease 9.7
313 coronary stenosis 9.7
314 neuromuscular disease 9.7
315 uremic neuropathy 9.7
316 chronic polyneuropathy 9.7
317 infertility 9.7
318 median neuropathy 9.7
319 panic disorder 9.7
320 esophageal disease 9.7
321 spinal stenosis 9.7
322 infiltrating lipoma 9.7
323 neuronitis 9.7
324 periodontitis 9.7
325 osteoarthritis 9.7
326 arthritis 9.7
327 herpes zoster 9.7
328 herpetic whitlow 9.7
329 nervous system disease 9.7
330 atrophic gastritis 9.7
331 macroglobulinemia 9.7
332 amyloidosis 9.7
333 hypereosinophilic syndrome 9.7
334 gdap1-related hereditary motor and sensory neuropathy 9.7
335 trichorhinophalangeal syndrome 9.7
336 mthfr gene variant 9.7
337 pyridoxine deficiency 9.7
338 brain injury 9.7
339 headache 9.7
340 hereditary neuropathies 9.7
341 traumatic brain injury 9.7
342 whiplash 9.7
343 posttransplant acute limbic encephalitis 9.7
344 neurotrophic keratopathy 9.7
345 cerebrofacial arteriovenous metameric syndrome 9.7
346 rare hereditary hemochromatosis 9.7
347 premature aging 9.7
348 rare surgical neurologic disease 9.7
349 central sleep apnea 9.7 REN ACE
350 renal hypertension 9.7 REN EPO ACE
351 acute cystitis 9.7 REN INS ACE
352 mineral metabolism disease 9.7 REN INS ACE
353 heart conduction disease 9.6 REN INS ACE
354 hypokalemia 9.6 REN INS ACE
355 pulmonary edema 9.6 REN EPO ACE
356 cardiac tamponade 9.6 REN ACE
357 parathyroid gland disease 9.6 REN INS GAST EPO
358 severe nonproliferative diabetic retinopathy 9.5 REN INS AKR1B1 ACE
359 retinal vascular disease 9.5 REN INS AKR1B1 ACE
360 alcoholic cardiomyopathy 9.5 REN ACE
361 inherited metabolic disorder 9.5 REN INS GCG ACE
362 cardiac arrest 9.5 REN EPO ACE
363 overnutrition 9.5 REN INS GCG ACE
364 glucose metabolism disease 9.5 REN INS GCG ACE
365 acquired metabolic disease 9.4 REN INS GCG ACE
366 functional gastric disease 9.4 PPY MLNR MLN INS GCG GAST
367 chronic pyelonephritis 9.4 REN ACE
368 cystic kidney disease 9.4 REN EPO ACE
369 end stage renal failure 9.4 REN GAST EPO ACE
370 nephrolithiasis, calcium oxalate 9.4 REN INS ACE
371 endocrine organ benign neoplasm 9.3 REN NGF INS GCG GAST
372 hypertension, essential 8.5 REN NGF INS GCG EPO ADAM8
373 autonomic nervous system disease 8.2 REN PPY NGF INS GCG AKR1B1

Graphical network of the top 20 diseases related to Diabetic Autonomic Neuropathy:



Diseases related to Diabetic Autonomic Neuropathy

Symptoms & Phenotypes for Diabetic Autonomic Neuropathy

UMLS symptoms related to Diabetic Autonomic Neuropathy:


sciatica, neuralgia

MGI Mouse Phenotypes related to Diabetic Autonomic Neuropathy:

45 (showing 1, show less)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.23 ACE ADAM8 AOC1 EPO INS NGF

Drugs & Therapeutics for Diabetic Autonomic Neuropathy

Drugs for Diabetic Autonomic Neuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(showing 273, show less)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
2
Bromocriptine Approved, Investigational Phase 4 25614-03-3 31101
3
tannic acid Approved Phase 4 1401-55-4
4
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
5
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
6
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
7
Nabilone Approved, Investigational Phase 4 51022-71-0 5284592
8
Amitriptyline Approved Phase 4 50-48-6 2160
9
Histamine Approved, Investigational Phase 4 51-45-6 774
10
Sodium citrate Approved, Investigational Phase 4 68-04-2
11
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
12
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
13
leucovorin Approved Phase 4 58-05-9 6006 143
14
Acetaminophen Approved Phase 4 103-90-2 1983
15
Cetirizine Approved Phase 4 83881-51-0 2678
16
Metformin Approved Phase 4 657-24-9 14219 4091
17
Hydrochlorothiazide Approved, Vet_approved Phase 4 58-93-5 3639
18
Gabapentin Approved, Investigational Phase 4 60142-96-3 3446
19
Donepezil Approved Phase 4 120014-06-4 3152
20
Ranolazine Approved, Investigational Phase 4 95635-55-5, 142387-99-3 56959
21
Folic acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
22
Citric acid Approved, Nutraceutical, Vet_approved Phase 4 77-92-9 311
23
Cyanocobalamin Approved, Nutraceutical Phase 4 68-19-9 44176380
24
Pyridoxine Approved, Investigational, Nutraceutical, Vet_approved Phase 4 65-23-6 1054
25
Pyridoxal Phosphate Approved, Investigational, Nutraceutical Phase 4 54-47-7 1051
26
Cobalamin Experimental Phase 4 13408-78-1 6857388
27
protease inhibitors Phase 4
28 HIV Protease Inhibitors Phase 4
29 Trace Elements Phase 4
30 Vitamins Phase 4
31 Micronutrients Phase 4
32 Antioxidants Phase 4
33 Vitamin B Complex Phase 4
34 Vitamin B9 Phase 4
35 Protective Agents Phase 4
36 Folate Phase 4
37 Nutrients Phase 4
38 Antirheumatic Agents Phase 4
39 Antimetabolites Phase 4
40 Dopamine agonists Phase 4
41 Alpha-lipoic Acid Phase 4
42 Thioctic Acid Phase 4
43 Anesthetics, Local Phase 4
44 Anesthetics Phase 4
45 Amitriptyline, perphenazine drug combination Phase 4
46 Anti-Arrhythmia Agents Phase 4
47 Anti-Inflammatory Agents Phase 4
48 Histamine H1 Antagonists Phase 4
49 Histamine Antagonists Phase 4
50
Histamine Phosphate Phase 4 51-74-1 65513
51 Anti-Allergic Agents Phase 4
52 Citrate Phase 4
53 Hypolipidemic Agents Phase 4
54 Anticholesteremic Agents Phase 4
55 Lipid Regulating Agents Phase 4
56 Anti-Inflammatory Agents, Non-Steroidal Phase 4
57 Analgesics, Non-Narcotic Phase 4
58 Vitamin B 12 Phase 4
59 Vitamin B 6 Phase 4
60 Vitamin B12 Phase 4
61 Antipyretics Phase 4
62 Linoleate Phase 4
63 Evening Primrose Phase 4
64 abobotulinumtoxinA Phase 4
65 Acetylcholine Release Inhibitors Phase 4
66 Botulinum Toxins Phase 4
67 Botulinum Toxins, Type A Phase 4
68 Histamine H1 Antagonists, Non-Sedating Phase 4
69 Phosphodiesterase Inhibitors Phase 4
70 Sildenafil Citrate Phase 4 171599-83-0
71 Phosphodiesterase 5 Inhibitors Phase 4
72 Omega 3 Fatty Acid Phase 4
73 Cholestyramine Resin Phase 4
74 Antihypertensive Agents Phase 4
75 Angiotensin-Converting Enzyme Inhibitors Phase 4
76 Hydroxymethylglutaryl-CoA Reductase Inhibitors Phase 4
77 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,... Phase 4
78 Sodium-Glucose Transporter 2 Inhibitors Phase 4
79 5-(4-chloro-3-(4-ethoxybenzyl)phenyl)-1-hydroxymethyl-6,8-dioxabicyclo(3.2.1)... Phase 4
80 Natriuretic Agents Phase 4
81 Angiotensin Receptor Antagonists Phase 4
82 Sodium Chloride Symporter Inhibitors Phase 4
83 diuretics Phase 4
84 Nootropic Agents Phase 4
85 Antimanic Agents Phase 4
86 Excitatory Amino Acids Phase 4
87 Cholinergic Agents Phase 4
88 Excitatory Amino Acid Antagonists Phase 4
89 Cholinesterase Inhibitors Phase 4
90 Sodium Channel Blockers Phase 4
91 Diuretics, Potassium Sparing Phase 4
92
Pyridoxal Experimental, Nutraceutical Phase 4 66-72-8 1050
93
Evening primrose oil Investigational, Nutraceutical Phase 4 308064-97-3
94
Dronabinol Approved, Illicit Phase 3 1972-08-3 16078
95
Allopurinol Approved Phase 3 315-30-0 2094
96
Capsaicin Approved Phase 3 404-86-4 1548943
97
Droxidopa Approved, Investigational Phase 3 23651-95-8 443940
98
Rosiglitazone Approved, Investigational Phase 3 122320-73-4 77999
99
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
100
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
101
Quinidine Approved, Investigational Phase 3 56-54-2 441074
102
Lacosamide Approved Phase 3 860352-01-8, 175481-36-4 219078
103
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
104
Mexiletine Approved, Investigational Phase 3 31828-71-4 4178
105
Peppermint oil Approved, Investigational Phase 3 8006-90-4
106
Peppermint Approved Phase 3
107
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
108
Oxybutynin Approved, Investigational Phase 3 5633-20-5 4634
109
Eslicarbazepine acetate Approved Phase 3 236395-14-5, 75970-99-9 123618
110
Oxycodone Approved, Illicit, Investigational Phase 3 76-42-6 5284603
111
Becaplermin Approved, Investigational Phase 3 165101-51-9
112
Tapentadol Approved Phase 3 175591-23-8 9838022
113
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 70-16-6, 59-43-8 1130
114
Choline Approved, Nutraceutical Phase 2, Phase 3 62-49-7 305
115
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
116
Ruboxistaurin Investigational Phase 3 169939-94-0, 202260-21-7 153999
117 Ranirestat Investigational Phase 3 147254-64-6
118 Nabiximols Investigational Phase 3 56575-23-6
119 Tocotrienol Investigational Phase 3 6829-55-6
120 Hormone Antagonists Phase 3
121 Antiemetics Phase 3
122 Hallucinogens Phase 3
123 Cannabinoid Receptor Agonists Phase 3
124 Antiparkinson Agents Phase 3
125 Gastrointestinal Agents Phase 2, Phase 3
126 Thiamin Phase 3
127 Autonomic Agents Phase 3
128 Respiratory System Agents Phase 3
129 Adrenergic alpha-Antagonists Phase 3
130 Cytochrome P-450 Enzyme Inhibitors Phase 3
131 Adrenergic Antagonists Phase 3
132 Anti-Infective Agents Phase 3
133 Antiprotozoal Agents Phase 3
134 Chlorpheniramine, phenylpropanolamine drug combination Phase 3
135 Antiparasitic Agents Phase 3
136 Antitussive Agents Phase 3
137 Cytochrome P-450 CYP2D6 Inhibitors Phase 3
138 Antimalarials Phase 3
139 Muscarinic Antagonists Phase 3
140 Cholinergic Antagonists Phase 3
141 Quinidine gluconate Phase 3
142 Anesthetics, General Phase 3
143 Anesthetics, Intravenous Phase 3
144 Adjuvants, Anesthesia Phase 3
145 Tocopherols Phase 3
146 Tocotrienols Phase 3
147 Renal Agents Phase 3
148 Mandelic Acids Phase 3
149 Anti-Infective Agents, Urinary Phase 3
150 Parasympatholytics Phase 3
151 Desvenlafaxine Succinate Phase 3 386750-22-7
152 Adrenergic Agents Phase 3
153 Anticoagulants Phase 3
154 Angiogenesis Inducing Agents Phase 3
155
Vildagliptin Approved, Investigational Phase 2 274901-16-5 6918537
156
Glucagon Approved Phase 2 16941-32-5
157
Clonidine Approved Phase 2 4205-90-7 2803
158
Ketamine Approved, Vet_approved Phase 2 6740-88-1 3821
159
Morphine Approved, Investigational Phase 2 57-27-2 5288826
160
Perphenazine Approved Phase 2 58-39-9 4748
161
Naloxone Approved, Vet_approved Phase 2 465-65-6 5284596
162
Nitroglycerin Approved, Investigational Phase 2 55-63-0 4510